ZyVersa Therapeutics, Inc.
ZVSA
$0.7625
-$0.0385-4.81%
| Weiss Ratings | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E | |||
| Reward Grade | E | |||
| Rating Factors | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.43 | |||
| Price History | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -19.24% | |||
| 30-Day Total Return | -44.75% | |||
| 60-Day Total Return | -27.39% | |||
| 90-Day Total Return | -62.06% | |||
| Year to Date Total Return | -30.05% | |||
| 1-Year Total Return | -90.46% | |||
| 2-Year Total Return | -99.90% | |||
| 3-Year Total Return | -99.98% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -92.15% | |||
| 52-Week Low % Change | 0.11% | |||
| Price | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.20 | |||
| 52-Week Low Price | $0.80 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | Mar 18, 2024 | |||
| Valuation | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.88M | |||
| Enterprise Value | 1.75M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -69.90 | |||
| Earnings Per Share Growth | -96.24% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.12 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.76 | |||
| Enterprise Value/EBITDA (TTM) | -0.18 | |||
| Enterprise Value/EBIT | -0.18 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 988.40K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 754 231 1688 | |||
| Address | 2200 N. Commerce Parkway Weston, FL 33326 | |||
| Website | www.zyversa.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.02% | |||
| Return on Equity | -- | |||
| Income Statement | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -9.62M | |||
| EBIT (TTM) | -9.63M | |||
| Net Income (TTM) | -21.33M | |||
| Net Income Avl. to Common (TTM) | -21.33M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 17.27% | |||
| EPS Diluted (TTM) | -69.90 | |||
| EPS Diluted Growth (Q YOY) | 91.95% | |||
| Balance Sheet | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 122.90K | |||
| Cash Per Share (Q) | $0.12 | |||
| Total Current Assets (Q) | 390.40K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 7.03M | |||
| Current Ratio (Q) | 0.034 | |||
| Book Value Per Share (Q) | $6.54 | |||
| Total Assets (Q) | 19.42M | |||
| Total Current Liabilities (Q) | 11.54M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 12.40M | |||
| Total Common Equity (Q) | 7.03M | |||
| Cash Flow | ZVSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 7.67M | |||
| Net Change in Cash (TTM) | -1.46M | |||
| Levered Free Cash Flow (TTM) | -5.33M | |||
| Cash from Operations (TTM) | -9.12M | |||
